by Stephane Cailmail | 12 Feb 2021 | General news, Publications, Research
Oncolytic viruses infect and replicate in cancer cells to induce cell death. As such, they are promising new therapies against cancer. This study describes for the first time the antitumor activity of SG33, a veterinary vaccine strain derived from the Myxoma virus....
by Stephane Cailmail | 8 Feb 2021 | General news, Publications, Research
Fibroblasts present in pancreatic tumours produce large amounts of proteins, which promote the proliferation of cancer cells, as well as their ability to metastasize. We have shown that these fibroblasts can be targeted using a somatostatin analogue SOM230, a molecule...
by Stephane Cailmail | 5 Feb 2021 | General news, Publications, Research
It is important to be able to identify and validate new therapeutic strategies for proteins that are not currently targeted by inhibitors in cancers. Therapeutic antibodies are molecules of choice for the standard treatment of many forms of cancer. Their application...
by Stephane Cailmail | 26 Jan 2021 | Publications, Research
Network medicine aims at using networks to uncover patterns in diseases and use them to understand their biology and propose new drugs. Since the appearance of Covid19, the disease provoked by the SARS-Cov-2 virus, the research community all around the globe has been...
by Stephane Cailmail | 4 Jan 2021 | General news, Publications, Research
Trabectedin is a cytotoxic drug used for the treatment of advanced soft tissue sarcoma. One of the most frequent side effects is hepatotoxicity, which occurs in nearly 40% of patients. In this pharmacogenetic study, we aimed to identify genetic polymorphisms that...
by Stephane Cailmail | 7 Dec 2020 | Publications, Research
An international team [1], led by Dr Ludovic Martinet (Inserm researcher) and Pr Hervé Avet-Loiseau from the Toulouse Cancer Research Centre (CRCT / Inserm, University of Toulouse III – Paul Sabatier, CNRS), has just published a study in the journal Immunity...
